AJTMH Transactions of the Royal Society of Tropical Medicine and Hygiene
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am. J. Trop. Med. Hyg., 49(1), 1993, pp. 106-112
Copyright © 1993 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Watkins, W. M.
Right arrow Articles by Marsh, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Watkins, W. M.
Right arrow Articles by Marsh, K.

Falciparum Malaria: Differential Effects of Antimalarial Drugs on Ex Vivo Parasite Viability during the Critical Early Phase of Therapy

William M. Watkins, Charles Woodrow AND Kevin Marsh
Coast Research Unit, Clinical Research Centre, Kenya Medical Research Institute (KEMRI), Nairobi, Kenya; Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom; St. Mary's Medical School, London, United Kingdom; Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom

A method of monitoring Plasmodium falciparum viability ex vivo was used to compare the ability of different antimalarial drugs to arrest the progression of young parasites to mature, potentially damaging stages. Neither pyrimethamine-sulfadoxine nor quinine, the treatment of choice for severe, life-threatening malaria, had a demonstrable effect on circulating parasites during the first 24 hr of therapy. In contrast, in vivo exposure to halofantrine for as little as six hours was sufficient to arrest parasite development. The method of assessing ex vivo parasite viability permits a comparison of antimalarial drug action at a time that may be critical for the therapy of life-threatening disease. If parenteral formulations of halofantrine prove to be safe and effective, they may have a role in the therapy of severe malaria.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the American Society of Tropical Medicine and Hygiene.